Full-Time

Associate Scientist

Structural Biology

Posted on 5/17/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$100k - $135kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Communications
Requirements
  • MSc. degree with 5+ years of experience or BSc. degree and a minimum of 8 years of experience
  • Experience with protein purification (AKTA) and/or biophysical characterization (Thermal melt, CD, SPR, anSEC).
  • Experience with protein-protein complexes including antibodies/Fabs, molecular glues, PROTACs, etc.
  • Experience with growing and harvesting protein crystals, preparing samples for CryoEM, prior use of structure determination/visualization software (CCP4, Phenix, Coot, PyMOL, Chimera), and/or CryoEM (Relion. CryoSPARC) are highly desirable skills.
  • Demonstrated ability to follow written protocols and document research progress.
  • Excellent written and verbal communication skills.
  • Conscientious team-player interested in a fast-paced biotech environment.
  • Demonstrated willingness to learn and improve processes.
Responsibilities
  • Preparation of protein complexes for structural analysis (Crystallography/CryoEM)
  • Operate laboratory robotics for preparing and inspection of crystallization trials.
  • Communicate experimental design and results to cross-functional teams.
  • Manage and document experiments.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

INACTIVE